Refractory myasthenia gravis: Characteristics of a portuguese cohort
- PMID: 31050006
- DOI: 10.1002/mus.26507
Refractory myasthenia gravis: Characteristics of a portuguese cohort
Abstract
Introduction: Some myasthenia gravis (MG) patients are refractory to conventional treatments.
Methods: To describe the clinical features of refractory MG (RMG) and explore the association with human leukocyte antigen HLA-DRB1 alleles, a cohort study of 114 consecutive MG patients was performed. Patients were classified as RMG based on predefined criteria.
Results: Twenty-two patients were found to have RMG (19.3%). There were no differences between non-RMG and RMG patients with respect to sex, age of onset, abnormal 3-Hz repetitive nerve stimulation, anti-acetylcholine receptor antibody positivity, thymectomy, thymoma or thymic hyperplasia, and polyautoimmunity. HLA-DRB1*03 was more frequent in the non-RMG vs. control population (P = 3 × 10-6 ). The HLA-DRB1*13 allele was less frequent in non-RMG patients compared with controls (P = 0.002), and less frequent in the non-RMG group compared with the RMG group (P = 0.003).
Discussion: HLA-DRB1*03 was more common in non-RMG, and the HLA-DRB1*13 allele appeared to have a protective role, as reported previously in other autoimmune disorders. Muscle Nerve 60: 188-191, 2019.
Keywords: human leukocyte antigens; myasthenia gravis; polyautoimmunity; refractory; thymoma MG.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis.Ann Clin Transl Neurol. 2021 Mar;8(3):656-665. doi: 10.1002/acn3.51309. Epub 2021 Feb 5. Ann Clin Transl Neurol. 2021. PMID: 33547763 Free PMC article.
-
High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis.Eur J Neurol. 2015 Jan;22(1):59-63. doi: 10.1111/ene.12525. Epub 2014 Jul 29. Eur J Neurol. 2015. PMID: 25070808
-
Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy.Acta Neurol Scand. 1994 Nov;90(5):318-23. doi: 10.1111/j.1600-0404.1994.tb02731.x. Acta Neurol Scand. 1994. PMID: 7887131
-
Whole-exome sequencing and human leukocyte antigen analysis in familial myasthenia gravis with thymoma: Case report and literature review.Clin Neurol Neurosurg. 2021 Sep;208:106864. doi: 10.1016/j.clineuro.2021.106864. Epub 2021 Aug 3. Clin Neurol Neurosurg. 2021. PMID: 34388596 Review.
-
Paraneoplastic myasthenia gravis: immunological and clinical aspects.Eur J Neurol. 2008 Oct;15(10):1029-33. doi: 10.1111/j.1468-1331.2008.02242.x. Epub 2008 Aug 20. Eur J Neurol. 2008. PMID: 18717725 Review.
Cited by
-
Rituximab for myasthenia gravis.Cochrane Database Syst Rev. 2025 Jul 3;7(7):CD014574. doi: 10.1002/14651858.CD014574.pub2. Cochrane Database Syst Rev. 2025. PMID: 40607605 Review.
-
Identification of Potential Key Genes for the Comorbidity of Myasthenia Gravis With Thymoma by Integrated Bioinformatics Analysis and Machine Learning.Bioinform Biol Insights. 2024 Sep 26;18:11779322241281652. doi: 10.1177/11779322241281652. eCollection 2024. Bioinform Biol Insights. 2024. PMID: 39345724 Free PMC article.
-
Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background.Pathophysiology. 2023 Dec 2;30(4):599-617. doi: 10.3390/pathophysiology30040043. Pathophysiology. 2023. PMID: 38133144 Free PMC article. Review.
-
Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.Neurol Sci. 2021 Jan;42(1):167-173. doi: 10.1007/s10072-020-04528-w. Epub 2020 Jun 26. Neurol Sci. 2021. PMID: 32592102
-
From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research.Front Neurol. 2020 Sep 2;11:981. doi: 10.3389/fneur.2020.00981. eCollection 2020. Front Neurol. 2020. PMID: 32982957 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials